January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

Organization highlights transformative approaches to clinical research, operational efficiency and patient-centric care at SCOPE US 2025 PH ...

Wall Street analysts forecast that Amgen (AMGN) will report quarterly earnings of $5.01 per share in its upcoming release, pointing to a year-over-year increase of 6.4%. It is anticipated that ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...

The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...

We recently compiled a list of the 7 Cheap Quarterly Dividend Stocks to Invest in. In this article, we are going to take a ...

Amgen (NASDAQ:AMGN – Free Report) had its price target decreased by Citigroup from $310.00 to $295.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...